scout
|Videos|December 7, 2017

Enzalutamide Shows Promise in HR+ Breast Cancer

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME